The global drug device combination market is expected to reach $17.7 billion by 2024, according to a new report from Grand View Research.
The report points to minimally invasive alternatives like transdermal patches as high-impact growth drivers in the industry.
As researchers develop these products, regulatory agencies have taken notice and the report notes that there is an increasing regulatory presence enforcing defined protocols for premarket authorizations.
This will support manufacturers in the development and approval process, authors write. Specifically, the report cites the FDA’s lean management approach to streamline and systematically review products.
Get the full story at our sister site, Drug Delivery Business News.